Founded in 1990, Chemz International PTE. LTD is a distinguished pharmaceutical conglomerate, integrating extensive research and development (R&D), production, and sales processes. With a robust workforce exceeding 15,000 employees, the company was publicly listed on the Hong Kong Stock Exchange in 2007 under the stock code: 3933.

Since its inception, Chemz International PTE. LTD has been dedicated to its core philosophy of “making life more valuable,” progressively diversifying its product range from antibiotics to biopharmaceuticals and veterinary pharmaceuticals. The company prides itself on its continuously optimized, vertically integrated business model. Currently, Chemz International boasts six state-of-the-art production facilities, with a diverse product portfolio that includes medical intermediates, active pharmaceutical ingredients (APIs), and comprehensive pharmaceutical preparations. These products are supported by an expansive global sales network, ensuring their availability worldwide.

Renowned for its formidable capabilities in R&D and production, coupled with a dynamic marketing strategy, Chemz International PTE. LTD has earned numerous accolades. These include ranking 22nd among the “China Top 100 Pharmaceutical Industry Companies in 2021,” being recognized as one of the “China Top 100 Industrial Enterprises with Comprehensive Strength in the Chemical Pharmaceutical Industry in 2020,” and securing the 16th position among “China Top 100 Chemical Pharmaceutical Enterprises in 2022.” Additionally, the company has been honored with titles such as “Excellent Enterprise Brand for Pharmaceutical Preparation Export” and “Excellent Enterprise Brand for APIs Export” within China’s Chemical Pharmaceutical Industry in 2021.

Through continuous innovation and a steadfast commitment to quality, Chemz International PTE. LTD remains at the forefront of the pharmaceutical industry, contributing significantly to global healthcare solutions.